Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.1552W HIGH $9.83
Volume
1.31 M
Value Traded
32.49 M
Short % Float
7.15%
Days to Cover
1.7
-4.35%Week
-14.71%1 Month
+48.38%3 Month
+88.06%6 Month
-91.95%5 Year
-37.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
830.41 M
EPS (TTM)
-4.59
P/E Ratio
-
Ent. Value
-193.39 M
Total Shares
78.71 M
Float Shares
48.45 M
Insiders
33.68%
Institutions
34.99%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
HELP Catalyst Timeline
Dated clinical, regulatory and corporate events for Cybin Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cybin Inc.
79Total events
6Upcoming
12Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
CEO Michael Halstead fireside chat at TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
▲Corporate ApprovalCorporate
Shareholders approve legal name change from Cybin Inc. to Helus Pharma Inc.
●Poster PresentationHLP003Presentation
Poster #1: Effects of HLP003 on MADRS Individual Items and Anhedonia Subscale in Adults With MDD
Major Depressive Disordersource ↗
●Long Term DataHLP003Clinical Data
12-month efficacy results from completed Phase 1/2a study of HLP003 presented
Major Depressive Disordersource ↗
▲Enrollment CompleteHLP003Trial
Completed enrollment in Phase 3 APPROACH study
Major Depressive Disordersource ↗
◆Oral PresentationPresentation
CEO Michael Halstead to participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference
▲Enrollment CompleteHLP003Trial
Completed enrollment in Phase 3 APPROACH study of HLP003 in MDD ahead of schedule
major depressive disordersource ↗
▲Enrollment MilestoneHLP003Trial
APPROACH Phase 3 trial surpassed 86% enrollment
major depressive disordersource ↗
◆Oral PresentationPresentation
Helus Pharma CMO to participate in fireside chat at H.C. Wainwright 7th Annual Neuro Perspectives Conference
◆Oral PresentationPresentation
Eric So to participate in fireside chat at Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Eric So, Interim CEO, to speak on panel 'The Next Wave of Health Innovation' at Milken Institute Global Conference
▲Partnership / LicenseCorporate
Helus Pharma partners with TARA Mind to support HLP003 Phase 3 recruitment and veteran outreach
▲Partnership / LicenseCorporate
Collaboration with TARA Mind to support HLP003 Phase 3 recruitment and expand veteran outreach
Major Depressive Disordersource ↗
▲Management ChangeCorporate
Appointment of Dr. Ken Kramer as Senior Vice President, Medical Affairs
▲Topline ReadoutHLP004Clinical Data
Topline results from Phase 2 signal detection study for HLP004 in GAD
generalized anxiety disordersource ↗
▲Full ResultsSPL026Clinical Data
Nature Medicine publishes Phase 2a results of SPL026 in MDD
major depressive disordersource ↗
◆Topline ReadoutHLP004Clinical Data
Phase 2 data for HLP004 expected in Q1 2026
Generalized Anxiety Disordersource ↗
◆Topline ReadoutCYB004Clinical Data
Phase 2 topline results for CYB004
generalized anxiety disordersource ↗
▲Full ResultsCYB003Clinical Data
12-month efficacy data for CYB003 Phase 2 study
major depressive disordersource ↗
▲Trial InitiationCYB003Trial
Phase 3 PARADIGM pivotal program initiated
major depressive disordersource ↗
●Oral PresentationPresentation
Conference call and webcast to discuss 12-month Phase 2 CYB003 results
▼Equity OfferingCorporate
Closed private placement, issued 348,837,210 shares for $150M gross proceeds
▼Equity OfferingCorporate
Underwritten public offering of 66,666,667 units at $0.45 per unit for gross proceeds of $30 million
◆Trial InitiationCYB003Trial
Plan to file clinical trial application with MHRA in Q2 2022
major depressive disorder and alcohol use disordersource ↗
◆Oral PresentationPresentation
CEO participates in fireside chat at H.C. Wainwright Bioconnect Conference
◆Oral PresentationPresentation
CEO participates in panel discussion at LifeSci Partners Corporate Access Event
◆Trial InitiationCYB003Trial
First-in-human clinical study for CYB003 expected in 2022
depressionsource ↗
◆Trial InitiationCYB004Trial
First-in-human clinical study for CYB004 expected in 2022
addiction disorderssource ↗
◆MHRA MilestoneCYB003Ex-US Regulatory
Scientific advice meeting with MHRA confirmed for Q1 2022
major depressive disorder and alcohol use disordersource ↗
▲First Patient DosedCYB003Trial
First-in-human studies expected for CYB003
mental health conditionssource ↗
▲First Patient DosedCYB004Trial
First-in-human studies expected for CYB004
mental health conditionssource ↗
▲Patent GrantedCYB004IP / Competition
USPTO Notice of Allowance for CYB004 patent application covering composition of matter
anxiety disorderssource ↗
◆Oral PresentationPresentation
Cybin CEO presentation at Stifel GMP 2nd Annual Future of Healthcare Conference
◆Oral PresentationPresentation
Cybin CEO fireside chat at H.C. Wainwright 2nd Annual Psychedelics Conference
◆Oral PresentationPresentation
Cybin CEO presentation at Jefferies London Healthcare Conference
▲Preclinical PoCCYB003Preclinical
Positive CYB003 pre-clinical data demonstrating advantages over oral psilocybin
Major Depressive Disorder, Alcohol Use Disordersource ↗
Past FDA Catalysts and PDUFA Decisions
How HELP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 47%
Micro Cap(rank 309 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CYB003 Small moleculeNCT06564818 | Major Depressive Disorder | Phase 3 | ACTIVE NOT_RECRUITING | 1,075 | Oct 1, 2026 | ||||||
| SPL026 Small moleculeCompletedNCT04673383 | Major Depressive Disorder | Phase 1 | COMPLETED | 98 | Dec 22, 2022 | ||||||
| CYB004 Small moleculeCompletedNCT06051721 | Generalized Anxiety Disorder | Phase 2 | COMPLETED | 36 | Aug 5, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every HELP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HLP004 | Generalized Anxiety Disorder | Phase 2 | 2026-03-05 | mean improvement of 10.4 points on the Hamilton Anxiety Rating Scale; 67% of participants responding positively after six months; 39% of patients were in remissionRead More | Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety DisorderRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cavers GregOfficer (Chief Financial Officer) | Buy | 3,000 3,000 held | $12.91 | 09/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HELP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HELP for Q2 2026. | ||||
HELP Institutional Ownership Trends
HELP Short Interest
Shares sold short, counted twice a month.
7.15%
Short % of Float
of tradable shares sold short
3.5M
Shares Sold Short
+7.4% vs prior count
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
2.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HELP ranks across every disease it competes in
Competitive Position is a premium feature
See how HELP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHELP News
HELP▲ +6.5%on this news
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Helus Pharma has appointed Dr. Suresh Durgam to its Board of Directors, bringing over 20 years of experience in CNS drug development. Previously the Chief Medical Officer at Intra-Cellular Therapies, Dr. Durgam has played a crucial role in securing FDA approvals for various CNS therapies. His expertise will support Helus Pharma's strategic goals as it advances its clinical pipeline.
Read more →HELPHelus Pharma to Host Investor Presentation on October 21, 2026
Helus Pharma Inc. will host an investor presentation on October 21, 2026, focusing on its proprietary serotonergic agonists HLP003 and HLP004, which are in Phase 3 and Phase 2 clinical trials, respectively. The event will feature discussions on the evolving treatment landscape for major depressive disorder and generalized anxiety disorder, along with a Q&A session with the executive team. The presentation aims to inform investors about the company's advancements in mental health treatments.
Read more →HELPHelus Pharma Announces Completion of Legal Name Change
Helus Pharma has officially changed its legal name from Cybin Inc. to Helus Pharma Inc., effective October 1, 2026. This change follows shareholder approval and reflects the company's transition towards becoming a commercial-ready pharmaceutical entity. Helus Pharma continues to focus on developing novel serotonergic agonists aimed at treating mental health conditions.
Read more →HELP▼ -5%on this news
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
Helus Pharma announced the results of its annual and special meeting held on September 22, 2026, where shareholders approved key resolutions, including the appointment of auditors and the election of directors. The company will officially change its name from Cybin Inc. to Helus Pharma Inc. on October 1, 2026, marking its transition to a commercial-ready pharmaceutical entity.
Read more →HELPHelus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Helus Pharma will have its CEO, Michael Halstead, participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The event will be webcast live, highlighting the company's commitment to developing novel serotonergic agonists for mental health conditions. Helus Pharma is currently advancing its proprietary NSAs, including HLP003 and HLP004, through various clinical phases.
Read more →HELP▲ +10.4%on this newsshared move
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Helus Pharma presented new analyses on HLP003 at Psych Congress 2026, showcasing its potential as an adjunctive treatment for major depressive disorder (MDD). The data included findings from a Phase 1/2a study and an overview of the ongoing Phase 3 PARADIGM program. The company aims to address unmet needs in mental health with its novel serotonergic agonists.
Read more →HELP▼ -6.1%on this news
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
Helus Pharma will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York. CEO Michael Halstead is scheduled for a fireside chat on September 16, 2026, at 8:30 a.m. EDT. This event highlights the company's engagement with the investment community and its ongoing clinical-stage initiatives.
Read more →HELP▲ +10.4%on this newsshared move
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
Helus Pharma is set to participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York. CEO Michael Halstead will engage in a fireside chat on September 14, 2026, at 9:00 a.m. EDT. This event presents an opportunity for the company to connect with investors and showcase its clinical-stage developments.
Read more →HELPHelus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
Helus Pharma will have its CEO, Michael Halstead, participate in a fireside chat at the Cantor Global Healthcare Conference in New York on September 11, 2026. The company is known for its development of novel serotonergic agonists aimed at treating mental health conditions. Helus Pharma is currently advancing its proprietary drugs HLP003 and HLP004 through clinical trials.
Read more →HELPHelus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
Helus Pharma has appointed Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board. Both executives come from Intra-Cellular Therapies, bringing significant experience in organizational growth and CNS drug development. Their expertise is expected to aid Helus Pharma in regulatory approvals and commercialization efforts.
Read more →HELPHelus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Helus Pharma has reported its financial results for the first quarter of fiscal 2027, highlighting key business developments. The company appointed Michael Halstead as Chief Executive Officer, aiming to guide Helus through late-stage development and commercialization. Additionally, Helus completed enrollment in the Phase 3 APPROACH study for its drug HLP003 targeting Major Depressive Disorder.
Read more →HELPHelus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
Helus Pharma is set to participate in the Canaccord Genuity 46th Annual Growth Conference in Boston. CEO Michael Halstead will engage in a fireside chat scheduled for August 12 at 12:00 p.m. EDT. This event presents an opportunity for the company to showcase its commitment to advancing mental health solutions.
Read more →HELPHelus Pharma Appoints Michael Halstead as Chief Executive Officer
Helus Pharma has appointed Michael Halstead as its new Chief Executive Officer. Halstead, a former President of Intra-Cellular Therapies, Inc., is recognized for his role in scaling the company, which was later acquired by Johnson & Johnson. His extensive experience in guiding pharmaceutical firms through late-stage clinical development is expected to enhance Helus Pharma's strategic direction.
Read more →HELP▲ +13.9%on this news
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
Helus Pharma has successfully completed enrollment in its Phase 3 APPROACH study of HLP003 for major depressive disorder ahead of schedule. This investigational drug aims to address treatment-resistant depression, and topline data is expected in Q4 2026. The broader market for mental health treatments is growing, with several companies advancing new therapies.
Read more →HELP▲ +13.9%on this newsshared move
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Helus Pharma has successfully completed enrollment in the Phase 3 APPROACH study of HLP003 for treating Major Depressive Disorder ahead of schedule. This study is part of the broader Phase 3 PARADIGM Program, which aims to evaluate the efficacy and safety of HLP003. The topline data readout is expected in Q4 2026.
Read more →HELP▲ +6.2%on this news
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Helus Pharma has successfully closed a $50 million underwritten offering, enhancing its financial stability. This funding will support the execution of the second Phase 3 trial for HLP003, named EMBRACE, which is aimed at a potential U.S. FDA New Drug Application in 2028. The company is optimistic about its future prospects with strong institutional investor backing.
Read more →HELP▲ +10.5%on this news
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Helus Pharma's Phase 3 trial for HLP003, aimed at treating major depressive disorder, has exceeded 86% enrollment, maintaining its timeline for topline data in Q4 2026. The drug has received FDA Breakthrough Therapy Designation, indicating its potential as a transformative treatment. However, the Phase 2 results remain unverified by the FDA, and the trial's outcomes are uncertain.
Read more →HELP▲ +18.3%on this news· ran to +30% by day 3shared move
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
Helus Pharma has successfully closed a $50 million underwritten offering of 10,309,280 common shares at $4.85 each. The proceeds will be used to advance its drug programs, particularly HLP003 for major depressive disorder, which is expected to have Phase 3 data by late 2026. The offering was managed by Cantor and Barclays, among others.
Read more →HELPHelus Pharma™ Announces US$50 Million Underwritten Offering
Helus Pharma has announced a $50 million underwritten offering of common shares at $4.85 each, expected to close on June 25, 2026. The proceeds will support the development of its serotonergic agonists, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder. The offering is subject to regulatory approvals and customary closing conditions.
Read more →HELPHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
Helus Pharma has announced that its APPROACH Phase 3 clinical trial for HLP003, aimed at treating major depressive disorder, is progressing well, with over 86% of enrollment completed. The previous Phase 2 trial results indicated a substantial long-term efficacy, showing a reduction of approximately 23 points on the Montgomery-Asberg Depression Rating Scale.
Read more →About Cybin Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next HELP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime